Inhibition of leukocyte trafficking in inflammatory bowel disease

New England Journal of Medicine

Volumn 369, Issue 8, 2013, Pages 775-776

  Cominelli, Fabio ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALPHA4BETA7 INTEGRIN; CERTOLIZUMAB PEGOL; INFLIXIMAB; INTEGRIN; NATALIZUMAB; PLACEBO; UNCLASSIFIED DRUG; VEDOLIZUMAB; VERCIRNON; VERY LATE ACTIVATION ANTIGEN 4;

CLINICAL TRIAL (TOPIC); CROHN DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; EDITORIAL; ENTERITIS; HUMAN; INFECTION RISK; LEUKOCYTE MIGRATION INHIBITION; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RISK ASSESSMENT; RISK REDUCTION; ULCERATIVE COLITIS;

EID: 84882785930     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1307415     Document Type: Editorial

References (5)

1. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-83. (Pubitemid 46695722)
2. Chen Y, Bord E, Tompkins T, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009;361:1067-74. [Erratum, N Engl J Med 2011;364:1882.]
3. Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-21.
4. Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
5. Keshav S, Vaňásek T, Niv Y, et al. A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's disease. PLoS ONE 2013;8(3):e60094.